Article Text

Download PDFPDF
Outcomes of polypoidal choroidal vasculopathy treated with ranibizumab monotherapy
  1. Colin S H Tan1,2,
  2. Wei Kiong Ngo1,
  3. Louis W Lim1,
  4. Kai Xiong Cheong1,
  5. Tock Han Lim1,2
  1. 1 Department of Ophthalmology, National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore, Singapore
  2. 2 Fundus Image Reading Center, National Healthcare Group Eye Institute, Singapore, Singapore
  1. Correspondence to Dr Colin S H Tan, Department of Ophthalmology, National Healthcare Group Eye Institute, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore; Colintan_eye{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with interest the article by Hikichi et al 1 describing the 2-year outcomes of intravitreal ranibizumab monotherapy for the treatment of patients with polypoidal choroidal vasculopathy (PCV). The authors reported significant improvement in visual acuity compared with baseline for both the first and second years, and a corresponding decrease in the mean foveal thickness measured on optical coherence tomography.

While these results are indeed encouraging, we feel that it is important to discuss the frequency of polyp regression and its implications on the long-term prognosis of patients with PCV. In the current study, the proportion of eyes in which no polypoidal lesions were detected on indocyanine green angiography was 40% 1 year after the first injection and …

View Full Text


  • Contributors Literature review: CST, WKN, LWL, KXC, THL. Formulation of the manuscript: CST, WKN, LWL, KXC, THL.

  • Competing interests None.

  • Provenance and peer review Not commissioned; externally peer reviewed.